Absorption of sulindac from a novel (Pro-Sorb™) liquid formulation

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 3, 1996, Pages 209-221

  Kanfer, I ^a   Brown, C ^a   Konings, M ^a   Swarbrick, J ^b  

^a RHODES UNIVERSITY   (South Africa)

^b AAI   (United States)

Author keywords

Liquid formulation; Pro Sorb ; Sulindac

Indexed keywords

DRUG METABOLITE; SULINDAC; SULINDAC SULFIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VOLUNTEER;

ABSORPTION; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSAGE FORMS; HUMANS; MALE; MIDDLE AGED; PRODRUGS; SINGLE-BLIND METHOD; SULINDAC;

EID: 0029987924     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199604)17:3<209::AID-BDD956>3.0.CO;2-6     Document Type: Article

References (18)

1. C. Dollery, Therapeutic Drugs, Vol. 2, Churchill Livingstone, Edinburgh, 1991, pp. S119-122.
2. R. K. Verbeeck, J. L. Blackburn and G. R. Loewen, Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs, Clin Pharmacokinet., 8, 297-331 (1983).
3. D. F. Duggan, L. E. Hare, C. A. Ditzler, B. W. Lei and K. C. Kwan, Disposition of sulindac, Clin. Pharmacol. Ther., 21, 326-335 (1977).
4. B. N. Swanson, V. K. Boppana, P. H. Vlasses, G. I. Holmes, K. Monsell and R. K. Ferguson, Sulindac disposition when given once and twice daily. Clin. Pharmacol. Ther., 397-403 (1982).
5. Pharmaceutical Manufacturers' Association (PMA), Drug Metabolism Subsection Workshop on Pharmacokinetics of Drug Metabolism, Bethesda, MD April 1989.
6. M.-L. Chen and A. J. Jackson, The role of metabolites in bioequivalence assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res., 8, 25-32 (1991).
7. M. R. Dobrinska, JD. E. Furst, T. Spiegel, W. C. Vincek, R. Tompkins, D. E. Duggan, R. O. Davies and H. E. Paulus, Biliary secretion of sulindac and metabolites in man. Biopharm. Drug Disposit., 4, 347-358 (1983).
8. S. Vozeh, O. Schmidlin and W, Taeschner, Pharmacokinetic drug data. Clin. Pkarmacokinet., 15, 254-282 (1988).
9. J. Mattila, R. Mäntylä, A. Vuorela, U. Lamminsivu and P. Männistö, Pharmacokinetics of graded oral doses of sulindac in man. Arzneim.-Forsch./Drug Res., 34, 226-229 (1984).
10. F. M. Plakogiannis and J. A. McCauley, Sulindac. In Analytical Profiles of Drug Substances, Vol. 13, K. Florey (Ed.), Academic, London, 1984, pp. 573-598.
11. H. C. Caldwell, Oral liquid compositions of non-steroidal anti-inflammatory drugs. U.S. Patent 5,183,829, 1993.
12. D. Sinar, P. Ellis, M. Beasley, D. Hong and J, Swarbrick, Gastric irritant potential of Pro-Sorb™ Liquid Sulindac and Clinoril Tablets in the monkey. Pharm. Res., 12, S108 (1995).
13. J. R. Lang and S. Bolton, A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry - 1. Experimental considerations. J. Pharm. Biomed. Anal., 9, 357-361 (1991).
14. S. V. Dighe and R. N. Patnaik, Need for metabolite analysis in bioequivalence studies. In Bio-international - Bioavailability, Bioequivalence and Pharmacokinetics, K. K. Midha and H. H. Blume (Eds), Medpharm, Stuttgart, 1993, pp. 149-161.
15. G. C. Graham, Pharmacokinetics and metabolism of non-steroidal anti-inflammatory drugs. Med. J. Aus t., 147, 597-602 (1987).
16. MIMS Desk Reference, Vol. 26, Times Media, Pretoria, 1990/91, pp. 697-699.
17. I. J. McGilveray, S. V. Digfae, L W. French, K. K. Midha and J. P. Skelly (Eds), Proceedings of Bio-Intemational '89 - Issues in the Evaluation of Bioavailability Data, Toronto, 1989, p. 217.
18. D. S. Sitar, J. A. Owen, B. MacDougall, T. Hunter and P. A. Mitenko, Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac. Clin. Pharmacol. Ther., 38, 228-234 (1985).